Critical Care Medicine Department, National Institutes of Health, Bldg 10 Room 2C142, 10 Center Dr, MSC 1662, Bethesda, MD 20892, USA.
JAMA. 2012 Jun 20;307(23):2534-9. doi: 10.1001/jama.2012.6445.
Ventilator-associated pneumonia (VAP) is among the most common infections in patients requiring endotracheal tubes with mechanical ventilation. Ventilator-associated pneumonia is associated with increased hospital costs, a greater number of days in the intensive care unit, longer duration of mechanical ventilation, and higher mortality. Despite widely accepted recommendations for interventions designed to reduce rates of VAP, few studies have assessed the ability of these interventions to improve patient outcomes. As the understanding of VAP advances and new technologies to reduce VAP become available, studies should directly assess patient outcomes before the health care community implements specific prevention approaches in clinical practice.
呼吸机相关性肺炎（VAP）是需要进行气管内插管和机械通气的患者中最常见的感染之一。VAP 与增加医院成本、增加重症监护病房天数、延长机械通气时间和增加死亡率有关。尽管有广泛接受的干预措施建议，旨在降低 VAP 发生率，但很少有研究评估这些干预措施改善患者结局的能力。随着对 VAP 的认识不断提高，以及减少 VAP 的新技术不断出现，在医疗保健界将特定的预防方法应用于临床实践之前，应直接评估患者的结局。
